AGN
Allergan Inc
Healthcare
11/10/2014
Presented
| Date | 11/05/2014 |
| Price | $N/A |
| Market Cap | $66.40B |
| Ent Value | $81.12B |
| P/E Ratio | N/A |
| Book Value | $110.00 |
| Div Yield | N/A |
| Shares O/S | 265.06M |
| Ave Daily Vol | 2,300,000 |
| Short Int | 780000.00% |
Current
| Price | $193.02 |
| Market Cap | $63.36B |
| Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. It operates in three segments: Actavis Pharma, Actavis Specialty Brands, and Anda Distribution. The Actavis Pharma segment provides generic, branded generic, and over-the-counter (OTC) pharmaceutical products. This segment sells generic prescription products primarily under the Watson Laboratories, Watson Pharma, and Actavis Pharma labels; and OTC generic products under private label. The Actavis Specialty Brands segment offers patent-protected products and trademarked off-patent products, which are marketed as branded pharmaceutical products to physicians, specifically urologists, obstetricians, dermatologists, gastroenterologists, and gynecologists. The Anda Distribution segment primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables, and OTC medicines to independent pharmacies, and to alternate care providers comprising hospitals, nursing homes, and mail order pharmacies, as well as to pharmacy chains, physicians’ offices, and buying groups. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, urology, gastroenterology, and dermatology therapeutic categories. The company has a collaboration agreement with Amgen, Inc. for the development and commercialization of various oncology antibody biosimilar medicines; and a collaboration agreement with Hanmi Pharm. Co. Ltd. to develop Hyalrheuma, a hyaluronic acid injection for arthritis pain treatment. Actavis plc was founded in 1983 and is headquartered in Parsippany, New Jersey. |
Publicly traded companies mentioned herein: Actavis plc (ACT), Allergan (AGN), Valeant (VRX), Salix Pharmaceuticals (SLXP), Pfizer (PFE) and AstraZeneca (AZN)
Highlights
The presenter sees shares of Actavis as offering excellent risk/reward and an attractive set-up in terms of potential near-term catalysts. The company is on the good side of the inversion trade by virtue of its acquisition of Forest Laboratories earlier this year, with no risk of retroactive government action. Brent Saunders, the former CEO of Forest who now heads Actavis, previously was credited with selling Bausch & Lomb. The presenter believes Saunders is a true capitalist who will do what is in the best interest of shareholders.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.